Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs
Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs
09/01/20, 11:03 AM
Location
seattleMoney raised
$16 million
Round Type
series b
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B financing. The financing was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital, with additional participation from existing investors Avista Development, Columbia Pacific, Lumen’s founders, and Seattle-area angels.
Company Info
Location
seattle, washington, united states
Additional Info
Lumen Bioscience discovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases—many of which currently lack any effective treatments. The company’s unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale and exponentially lower costs than current approaches. For more information, visit: www.lumen.bio.